Cellectis SA Combined General Shareholders' Meeting of June 14, 2013

Cellectis SA Combined General Shareholders' Meeting of June 14, 2013

  • Approval of the 18 resolutions proposed by the Board of Directors
  • Dr Mathieu Simon, Senior Vice President and CEO of Cellectis therapeutics, elected to the Board of Directors of Cellectis SA
  • Presentation of the Group's therapeutics strategy

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cellectis (Alternext: ALCLS) held its Combined General Shareholders' Meeting on Friday, June 14, 2013 in Paris, at the Group's headquarters.


Nearly 60% of voting rights were expressed at the Meeting, 18 of the 19 resolutions were approved and 14 resolutions received more than 90% positive votes. The resolution that did not have the Board of Directors' recommendation was rejected.

The decisions made by Cellectis' shareholders included:

  • approving the parent company and consolidated financial statements for the fiscal year ended December 31, 2012;
  • approving regulated agreements;
  • nominating a new Director, Mathieu Simon, CEO of Cellectis therapeutics;
  • authorizing a share repurchase plan and authorizing the Board of Directors to retire the shares acquired through it;
  • various delegations of authority and financial authorizations granted to the Board of Directors.

The complete voting results are available on the Group's website (www.cellectis.com).

The Combined General Shareholders' Meeting was an opportunity for Chairman and CEO André Choulika to review key aspects of the Group's activity over the past fiscal year, and to highlight the impact of management initiatives that enabled the Group to refocus on core programs. He also shed light on work done by the Board of Directors, and changes to how Cellectis is governed.

After these presentations, Dr Mathieu Simon, CEO of Cellectis therapeutics, focused on the Company's development strategy in therapeutics, where the Group is at the forefront of fields such as regenerative medicine (in the fight against type 1 diabetes) and cancer immunotherapy (chronic lymphoid leukemia, or CLL).

At the end of the Annual General Shareholders' Meeting, André Choulika commented, "Through their strong presence at this year's General Shareholders' Meeting and their votes, our shareholders have clearly shown their confidence in the actions taken by executive management and in the strategy validated by the Board of Directors. I would like to extend our warmest gratitude to them."

Cellectis' Chairman and CEO went on to express his satisfaction with the appointment of Dr Mathieu Simon to the Company's Board of Directors. "Since joining the Group, Mathieu Simon has been instrumental in moving Cellectis Group's therapeutics strategy forward and his contributions have proved successful. Now that he is a member of the Board of Directors, we will reap even more benefits from his vision of the pharmaceutical industry, his internationally recognized expertise and his enthusiasm, all of which will serve us in good stead during this important structuring phase for the Company."

About Cellectis

Founded in France in 1999, the Cellectis Group bases its work on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Cellectis was co-founded by André Choulika, its Chairman and CEO, and is now one of the world's top companies in the field of genome engineering, with revenue of $27 million in 2012. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, toxicity testing, and regenerative medicine. Cellectis has a solid background in the large-scale handling of stem cells up until their maturation and differentiation into functional cell types. We employ a workforce of 230 people at 5 sites worldwide: New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States, Gothenburg in Sweden, and Paris & Evry in France.

The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. Our clients and partners include University College London (UCL), the National Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell Research and Application (CiRA) of Kyoto University, AFM, Novartis, BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.

For more information, visit our website: www.cellectis.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country.



Cellectis
Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
media@cellectis.com
Calyptus
Mathieu Calleux / Marie-Anne Garigue
Tel: +33 (0)1 53 65 68 68
cellectis@calyptus.net

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:

The article Cellectis SA Combined General Shareholders' Meeting of June 14, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Behavioral Finance

Why do investors make the decisions that they do?

View Course »

Introduction to ETFs

The basics of Exchange Traded Funds and why ETFs are hot.

View Course »

Add a Comment

*0 / 3000 Character Maximum